Rhythm Pharmaceuticals Inc RYTM:NASDAQ

Last Price$24.02Cboe Real-Time Last Sale as of 11:44AM ET 8/17/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.81(3.26%)
Bid (Size)$23.94 (202)
Ask (Size)$24.03 (309)
Day Low / High$23.86 - 25.69
Volume237.9 K
 

View Biotechnology IndustryPeer Comparison as of 08/17/2022

 

Rhythm Pharmaceuticals Inc ( NASDAQ )

Price: $24.02
Change: -0.81 (3.26%)
Volume: 237.9 K
11:44AM ET 8/17/2022
 
 

ImmunoGen Inc ( NASDAQ )

Price: $5.88
Change: -0.06 (1.01%)
Volume: 667.5 K
11:44AM ET 8/17/2022
 
 

Avid Bioservices Inc ( NASDAQ )

Price: $19.00
Change: -0.36 (1.86%)
Volume: 55.5 K
11:39AM ET 8/17/2022
 
 

Editas Medicine Inc ( NASDAQ )

Price: $16.23
Change: -1.11 (6.40%)
Volume: 418.1 K
11:44AM ET 8/17/2022
 
 

Rocket Pharmaceuticals Inc ( NASDAQ )

Price: $17.20
Change: -0.73 (4.07%)
Volume: 66.4 K
11:44AM ET 8/17/2022
 

Read more news Recent News

Rhythm Pharmaceuticals Shares Rise After Goldman Sachs Upgrade
11:23AM ET 8/08/2022 MT Newswires

Rhythm Pharmaceuticals (RYTM) shares rose more than 10% in recent trading activity on Monday after Goldman Sachs upgraded the company's rating to buy from...

--Goldman Sachs Upgrades Rhythm Pharmaceuticals to Buy From Neutral; Price Target is $28
5:35AM ET 8/08/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--BofA Securities Upgrades Rhythm Pharmaceuticals to Neutral From Underperform, Adjusts Price Target to $20 From $8
6:23AM ET 8/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Morgan Stanley Raises Rhythm Pharmaceuticals' Price Target to $16 From $8, Keeps Equalweight Rating
11:37AM ET 8/03/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionRhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA. View company web site for more details
Address222 Berkeley Street
Boston, Massachusetts 02116-3748
Phone+1.857.264.4280
Number of Employees54
Recent SEC Filing08/03/202210-Q
Chairman, President & Chief Executive OfficerDavid P. Meeker
Chief Financial Officer & TreasurerHunter C. Smith
Vice President-Medical AffairsBrieana Buckley
Chief Technical OfficerJoseph Shulman

Company Highlights

Price Open$24.78
Previous Close$24.83
52 Week Range$3.04 - 27.29
Market Capitalization$1.2 B
Shares Outstanding50.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/01/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.49
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-1,310.60%
Return on Equity-67.73%

Analyst Ratings as of 08/05/2022

Buy
6
Overweight
0
Hold
2
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset